Does vivitrol completely stop cravings for alcohol?

Does Vivitrol stop alcohol cravings completely?

Vivitrol reduces alcohol cravings for many people but does not eliminate them in every case. The medication blocks opioid receptors that reinforce drinking, which can lower the urge to drink and reduce heavy drinking days, yet individual responses vary based on dose timing, concurrent therapy, and personal neurochemistry.

How long does it take for Vivitrol to reduce cravings?

Most patients notice a drop in cravings within the first week after the initial injection. Peak effect occurs around two to four weeks, after which the monthly dose maintains steady receptor blockade until the next injection.

Can someone still drink while on Vivitrol?

Yes. Vivitrol does not cause a severe reaction like disulfiram, so alcohol consumption remains possible. The drug simply makes drinking feel less rewarding, which helps some patients cut back even if they slip and have a drink.

What happens if cravings return before the next shot?

Cravings can increase in the final week of the 28-day dosing interval as naltrexone levels decline. Clinicians sometimes adjust injection timing or add oral naltrexone on days 25–28 to bridge the gap for patients who experience this pattern.

How does Vivitrol compare with daily naltrexone tablets?

Both forms contain the same active ingredient, but Vivitrol guarantees adherence for a full month. Daily tablets require consistent self-administration; missed doses allow receptor activity to rebound and cravings to return. Some patients prefer the injection for convenience, while others find daily dosing gives more control over side-effect timing.

When does the Vivitrol patent expire?

The primary U.S. patent covering the extended-release microsphere formulation expires in 2026, although pediatric exclusivity may extend protection to 2027. After expiry, generic versions could enter the market and lower cost.

Who makes Vivitrol and are there competitors?

Alkermes manufactures Vivitrol. No direct long-acting injectable naltrexone competitors are approved in the U.S., but oral naltrexone, acamprosate, and disulfiram remain widely available alternatives. Several companies are developing competing depot formulations that could reach the market after 2026.

[1] https://www.drugpatentwatch.com/drug/Vivitrol